Evidence map›Paper›PMID 38918410›Full record

ArticleScientific reports2024

Investigation of the antimycobacterial activity of African medicinal plants combined with chemometric analysis to identify potential leads.

Phanankosi Moyo, Michael Ofori, Olusola S Bodede, Madelien Wooding, Ndivhuwo Kevin Khorommbi, Lyndy J McGaw, Cynthia A Danquah, Vinesh J Maharaj

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Phanankosi Moyo *Biodiscovery Center, Department of Chemistry, University of Pretoria, Hatfield, Private Bag X 20, Pretoria, 0028, South Africa.
Michael Ofori *Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, PMB, Kumasi, Ghana.
Olusola S BodedeBiodiscovery Center, Department of Chemistry, University of Pretoria, Hatfield, Private Bag X 20, Pretoria, 0028, South Africa.
Madelien WoodingBiodiscovery Center, Department of Chemistry, University of Pretoria, Hatfield, Private Bag X 20, Pretoria, 0028, South Africa.
Ndivhuwo Kevin KhorommbiBiodiscovery Center, Department of Chemistry, University of Pretoria, Hatfield, Private Bag X 20, Pretoria, 0028, South Africa.
Lyndy J McGawPhytomedicine Programme, Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, Private Bag X04, Pretoria, 0110, South Africa.
Cynthia A DanquahDepartment of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, PMB, Kumasi, Ghana. cadanquah.pharm@knust.edu.gh.
Vinesh J MaharajBiodiscovery Center, Department of Chemistry, University of Pretoria, Hatfield, Private Bag X 20, Pretoria, 0028, South Africa. vinesh.maharaj@up.ac.za.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of drug-resistant Mycobacterium tuberculosis strains is a threat to global health necessitating the discovery of novel chemotherapeutic agents. Natural products drug discovery, which previously led to the discovery of rifamycins, is a valuable approach in this endeavor. Against this backdrop, we set out to investigate the in vitro antimycobacterial properties of medicinal plants from Ghana and South Africa, evaluating 36 extracts and their 252 corresponding solid phase extraction (SPE) generated fractions primarily against the non-pathogenic Mycobacterium smegmatis and Mycobacterium aurum species. The most potent fraction was further evaluated in vitro against infectious M. tuberculosis strain. Crinum asiaticum (bulb) (Amaryllidaceae) emerged as the most potent plant species with specific fractions showing exceptional, near equipotent activity against the non-pathogenic Mycobacterium species (0.39 µg/ml ≤ MIC ≤ 25 µg/ml) with one fraction being moderately active (MIC = 32.6 µg/ml) against M. tuberculosis. Metabolomic analysis led to the identification of eight compounds predicted to be active against M. smegmatis and M. aurum. In conclusion, from our comprehensive study, we generated data which provided an insight into the antimycobacterial properties of Ghanaian and South African plants. Future work will be focused on the isolation and evaluation of the compounds predicted to be active.

Indexed as

Microbial Sensitivity TestsMycobacterium tuberculosisPlant ExtractsPlants, MedicinalAnti-Bacterial AgentsAntitubercular AgentsGhanaHumansMycobacteriumMycobacterium smegmatisSouth AfricaAnti-Bacterial AgentsAntitubercular AgentsPlant ExtractsAntimicrobial drug resistanceMetabolomicsMycobacterium tuberculosisNatural productsPlantsTuberculosis

Identifiers

PMID38918410
PMCPMC11199645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.